logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Mepolizumab for chronic rhinosinusitis with nasal polyposis,in addition to standard care

< Back

Mepolizumab for chronic rhinosinusitis with nasal polyposis,in addition to standard care

Drugs

Ear, Nose and Throat

May 2020


Mepolizumab is in development for the treatment of chronic rhinosinusitis with polyposis (polyps) (CRSwNP). Nasal polyps are characterised by oedema (swelling) and accumulation of a type of white blood cell called eosinophils. Nasal polyps cause symptoms such as nasal blockage, loss of smell and rhinorrhoea (frequent runny nose). The cause of CRSwNP is not completely understood, however, it is more common in people with other conditions including asthma. In addition, CRSwNP has been linked to having high levels of a protein called IL-5, which interacts with eosinophils and promotes their development.

Mepolizumab is an antibody that binds to IL-5 to prevent it from interacting with its receptor on the surface of eosinophils. This binding prevents their maturation, differentiation, mobilisation, activation and survival; thereby controls their activity. Mepolziumab is administered subcutaneously. If licenced, mepolizumab will offer an additional treatment option –on top of standard care – for patients with CRSwNP, who frequently suffer from uncontrolled symptoms and disease recurrence.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts